Cramer says a trio of recent deals demands attention.
Stocks kicked off the week on a weak note as investors hesitated to jump in ahead of the Federal Reserve meeting and a slew of key economic reports.
This is a big week for macro news: a Federal Reserve meeting, an advance look at second-quarter U.S. growth, and July's nonfarm payroll report. But the bigger story may be the weakness of the U.S. dollar.
U.S. stock index futures ticked lower on Monday, ahead of the Federal Reserve meeting and another heavy week for second quarter earnings.
The Federal Reserve's taper talk may have rattled the financial markets but it has had one notable beneficiary: Mergers and acquisitions.
U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatment and tax savings from being domiciled in Ireland.
Perrigo CEO Joe Papa discusses the biotech industry, the state of the consumer and why Mucinex is going to be a big winner for his company.
As the economy stalled, many people opted for store brand medicines. But as the economy improves, will the trend reverse?
The Forensic Accounting ETF launches today. The fund spotlights a concept that is often woefully overlooked.
ALLEGAN, Mich.-- Perrigo Co., which makes store-brand over-the-counter drugs and infant formulas, said Wednesday that it received approval from the U.S. Food and Drug Administration to market an over-the-counter nicotine product similar to Nicorette mini lozenges.
*Receives FDA approval to market mini nicotine lozenges.
You’ve heard about all those big stocks that you should buy, but the pros say there are plenty of mid-size names that belong on your radar too.
Perrigo CEO Joseph Papa appeared on Wednesday's "Mad Money."
Perrigo CEO, Joseph Papa discusses his company's 11% Q2 profit rise, and its outlook on growth, with Mad Money's Jim Cramer.
A lot of people aren’t doing their homework and those people are losing money.
When it comes to combating financial markets that all seem to move in unison, the options are getting so limited that some are questioning whether stock picking is a dying art.
Cramer and his researcher, Nicole Urken, discuss why homework—particularly during earnings season—remains important to recognizing the stock winners of the coming years.
Joseph Papa sits down with Cramer and explains why things are looking good for the private label drug maker.
Mad Money host Jim Cramer takes a look at Perrigo, which develops, manufactures and distributes private label goods to retailers. Joseph Papa, chairman, president & CEO of Perrigo, weighs in. "Our products are popular in both bull and bear markets," he says.
The “Mad Money” host explains why Europe’s problems trump good news out of the US.